Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know - 2Elite Execution Wall televisions for Film Darlings
- 3'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- 4Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands
- 5The Force of Positive Reasoning: Day to day Attestations
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- The Best 15 Applications for Efficiency and Association
- Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage
- Warning for snow and ice extended
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Vote In favor of Your #1 Compelling Female Producer
- The Most Compelling Innovation Advancements Somewhat recently
- What are the health benefits of whole milk for kids?
